Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
OPKO Health presented preclinical data for OPK8801001, a novel long-acting growth hormone receptor antagonist, at the ENDO 2026 conference. In vitro data showed the candidate is approximately 20-fold more potent than Pegvisomant, the current standard of care for acromegaly.
Key figures
- Drug Name
- OPK8801001
- Potency vs comparator
- 20-fold greater than Pegvisomant
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.